SBIR/STTR Research Award
Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury
Award amount
$240,656Program and phase
STTR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- INFLAMACORE LIMITED LIABILITY COMPANY
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- F7H9PNARMES3
- Solicitation number
- PA13-089
- Topic code
- NINDS
Research abstract
PROJECT SUMMARY Spinal cord injury (SCI) is a complex and devastating clinical condition mediated by proinflammatory cytokines that produce neuronal loss, axonal destruction, and demyelination during the secondary injury cascade. There are currently no proven therapies targeting posttraumatic inflammation that have been shown to have clinical value. We have previously shown that central nervous system (CNS) neurons express the NLRP1 inflammasome, a multiprotein complex that regulates the activation of caspase-1 and the pro-inflammatory cytokines IL-1 and IL-18 production after spinal cord injury, traumatic brain injury and stroke. The adaptor protein apoptosis associated speck-like protein containing a caspase activating recruitment domain (ASC) is important for the recruitment of inflammasome proteins into the multiprotein complex that activates caspase-1. The long-term goal of this project is to develop an anti-inflammatory therapy that improves outcomes after SCI in humans. The objective of this applica
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Enhancing Healthcare Delivery and Patient Outcomes: Noninvasive Wireless Sensors to Improve Ventricular Shunt Monitoring, Reduce Imaging, and Alleviate the Burden on Providers, Patients, and Families
- Commercialization Readiness Pilot for Flow Acceleration for Stroke Thrombolysis (FAST) System
- 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development
- Tacrolimus-eluting nerve guidance conduit for enhanced regeneration in critical-sized peripheral nerve injuries
- Promoting tissue repair and functional recovery after spinal cord injury by targeting the microtubule regulatory protein Fidgetin-like 2: Supplement for Imaging System
Research funding history
2 SBIR/STTR records share this UEI (2014–2015). Reported award amounts total $1,543,676. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services